News

OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

First clinical trial to evaluate the safety and efficacy of …

Poster Presentation at AACR 2021 Annual Meeting for OBI-3424, OBI-998, GLOBO H and SSEA-4

Title: Selective and Broad Anti-tumor Activity of AKR1C3-activated Prodrug AST-3424/OBI-3424 …

OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 …

OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

Taipei, Taiwan. January 6, 2021 — OBI Pharma, Inc., a …

ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

1. Presentation number: 397P / Poster: ID 680 Title: A …

OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

Presentations to highlight the OBI-833 Phase 1 clinical study results …

Company Announcement on Board Resolutions

Please refer to https://www.obipharma.com/2020/09/company-announcement-on-board-resolution/?lang=zh-hant for details.

OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

Presentation to highlight the scientific characteristics of the novel first-in-class …

Poster Presentations at AACR 2020 Virtual Annual Meeting II

Session PO ET04.02 Identification of molecular targets 2 Title: The …

OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II

Poster Presentations to highlight the role of the Globo H …